Drug intelligence / Profile preview

L04TD1

Development stage: Unknown
Lead developer: Celltrion
Administration: Oral

Overview

L04TD1 is a drug developed by Celltrion. It is currently undergoing a Phase 1 clinical study to evaluate its safety, tolerability, and pharmacokinetics in healthy adult volunteers. The study also aims to assess the bioequivalence of L04TD1 when administered as a single tablet, in comparison to L04RD1.

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on L04TD1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L04TD1.

Explore the full profile